246 related articles for article (PubMed ID: 23585456)
1. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.
Cen B; Mahajan S; Wang W; Kraft AS
Cancer Res; 2013 Jun; 73(11):3402-11. PubMed ID: 23585456
[TBL] [Abstract][Full Text] [Related]
2. Rational cotargeting of Pim-1 and Akt in prostate cancer.
Toren P; Zoubeidi A
Expert Rev Anticancer Ther; 2013 Aug; 13(8):937-9. PubMed ID: 23984895
[TBL] [Abstract][Full Text] [Related]
3. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
4. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
5. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
[TBL] [Abstract][Full Text] [Related]
7. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.
Song JH; Singh N; Luevano LA; Padi SKR; Okumura K; Olive V; Black SM; Warfel NA; Goodrich DW; Kraft AS
Mol Cancer Ther; 2018 Dec; 17(12):2710-2721. PubMed ID: 30190422
[TBL] [Abstract][Full Text] [Related]
9. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S; Kumar C; Sathyadevan VK; Simpson BS; Gately KA; Whitaker HC; Heavey S
Signal Transduct Target Ther; 2020 Jan; 5(1):7. PubMed ID: 32296034
[TBL] [Abstract][Full Text] [Related]
10. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Chandarlapaty S; Sawai A; Scaltriti M; Rodrik-Outmezguine V; Grbovic-Huezo O; Serra V; Majumder PK; Baselga J; Rosen N
Cancer Cell; 2011 Jan; 19(1):58-71. PubMed ID: 21215704
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.
Padi SKR; Singh N; Bearss JJ; Olive V; Song JH; Cardó-Vila M; Kraft AS; Okumura K
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20505-20510. PubMed ID: 31548394
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
13. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
[TBL] [Abstract][Full Text] [Related]
14. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.
Gu M; Roy S; Raina K; Agarwal C; Agarwal R
Cancer Res; 2009 Dec; 69(24):9465-72. PubMed ID: 19920184
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
[TBL] [Abstract][Full Text] [Related]
16. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
17. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Rodrik-Outmezguine VS; Chandarlapaty S; Pagano NC; Poulikakos PI; Scaltriti M; Moskatel E; Baselga J; Guichard S; Rosen N
Cancer Discov; 2011 Aug; 1(3):248-59. PubMed ID: 22140653
[TBL] [Abstract][Full Text] [Related]
18. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
[TBL] [Abstract][Full Text] [Related]
19. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
20. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.
Chang M; Kanwar N; Feng E; Siu A; Liu X; Ma D; Jongstra J
Mol Cancer Ther; 2010 Sep; 9(9):2478-87. PubMed ID: 20667852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
